Compare MSGY & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSGY | ENVB |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 6.7M |
| IPO Year | 2024 | 2000 |
| Metric | MSGY | ENVB |
|---|---|---|
| Price | $4.27 | $1.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.2M | 63.3K |
| Earning Date | 07-30-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.89 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.23 | $0.57 |
| 52 Week High | $11.42 | $13.25 |
| Indicator | MSGY | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 55.44 | 52.72 |
| Support Level | $0.85 | $1.17 |
| Resistance Level | $5.88 | $1.53 |
| Average True Range (ATR) | 1.62 | 0.09 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 25.39 | 41.77 |
Masonglory Ltd is a a holding company and operates through subsidiary. It is engaged in the provision of wet trades services and other ancillary services as a subcontractor in Hong Kong. As a subcontractor, It provide customers with comprehensive wet trades works solutions, which principally include plastering on floors, ceilings and walls, tile laying on internal and external walls and floors, brick laying, floor screeding, and marble works.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.